Understanding how extracorporeal photochemotherapy causes cell death
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
This study is trying to understand how a treatment called extracorporeal photochemotherapy helps patients with skin lymphomas and graft-versus-host disease by looking at how it causes certain cells to die.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT05333367 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the mechanisms of cell death induced by extracorporeal photochemotherapy (ECP) in patients with conditions such as cutaneous T-cell lymphoma and graft-versus-host disease. By collecting and treating leukocytes from patients, the study will analyze the type of cell death that occurs based on the cell type and the therapeutic context. The research will utilize various complementary analysis techniques to provide insights into the immunomodulatory effects of ECP and its potential to enhance treatment outcomes. The findings could help refine therapeutic regimens for patients undergoing ECP.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients who have been treated with extracorporeal photochemotherapy for at least one month for conditions like graft-versus-host disease or cutaneous T-cell lymphoma.
Not a fit: Patients who are pregnant, have limited legal capacity, or are currently participating in another clinical trial may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with cutaneous T-cell lymphoma and those undergoing organ transplantation.
How similar studies have performed: While the mechanisms of ECP are not fully understood, similar studies have shown promise in understanding cell death pathways in other therapeutic contexts, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients * Treated with ECP for at least 1 month, for control of GVHD in hematopoietic cell allograft (acute or chronic GVHD), treatment and control of cellular or humoral rejection in solid organ transplantation (heart, lung, kidney) or in the treatment of cutaneous T-cell lymphoma Exclusion Criteria: * Subjects with limited legal capacity. * Subjects judged by the investigator to be unlikely to comply with study procedures * Subjects with no social security coverage. * Pregnant women. * Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.
Where this trial is running
Besançon
- Centre Hospitalier Universitaire de Besançon — Besançon, France (Recruiting)
Study contacts
- Study coordinator: Charline VAUCHY, PhD
- Email: cvauchy@chu-besancon.fr
- Phone: +33381218875
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.